Effectiveness of Topiramate augmentation compared with placebo in chronic schizophrenia admitted to Ebnesina and Hejaze Hospitals in Mashad

Mashad university of medical sciences0 个研究点目标入组 80 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•Inclusion criteria
•1. All the patients who meet the full criteria of chronic and treatment resistant schizophrenia disorder, based on DSMIV-TR
•2. Ages of subjects were between 25 to 65 years
•3. All patients were hospitalized for at least 6 month before the study
•4. All patients were being treated with Clozapin
•Exclusion criteria
•1. Chronic diseases including diabetes, hypertension, history of kidney stone, epilepsy and substance abuse
•2. An ongoing medical treatment
•3. Elevated PANSS score up to 30%
•4. Adverse effects associated with therapy including dizziness, agitation, hypertension, allergy to medications
•5. Medical problems need to be treated such as diarrhea, urinary infection, cardiovascular disease, and trauma.
•6. Temporary or permanent discharge from hospital while in study
•7. Developing new psychiatric symptoms such as manic or hypomanic episode, panic attack

发起方

Mashad university of medical sciences